Axonics Modulation Technologies Inc Cash Flow Conversion Efficiency
Axonics Modulation Technologies Inc cash flow conversion efficiency. Based on the latest financial reports, Axonics Modulation Technologies Inc (AXNX) has a cash flow conversion efficiency ratio of 0.001x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($922.00K) by net assets ($664.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AXNX stock market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Axonics Modulation Technologies Inc (2016–2023)
Cash flow conversion efficiency of Axonics Modulation Technologies Inc from 2016 to 2023. This chart illustrates how Axonics Modulation Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Axonics Modulation Technologies Inc share price for real-time trading data and today's change.
Axonics Modulation Technologies Inc Cash Flow Conversion Ratio Explained
Axonics Modulation Technologies Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Axonics Modulation Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axonics Modulation Technologies Inc ranked by their cash flow conversion efficiency. Review AXNX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
0.338x |
|
JOSAPAR Joaquim Oliveira S.A. Participações
SA:JOPA3
|
-0.065x |
|
Tela Bio Inc
NASDAQ:TELA
|
0.591x |
|
Honmyue Enterprise Co Ltd
TW:1474
|
0.029x |
|
Triller Group Inc. Common Stock
NYSE:ILLR
|
0.013x |
|
American Tungsten & Antimony Ltd
AU:AT4
|
-0.417x |
|
Fiyta Holdings Ltd
SHE:200026
|
0.040x |
|
Petershill Partners PLC
LSE:PHLL
|
0.014x |
Annual Cash Flow Conversion Efficiency for Axonics Modulation Technologies Inc (2016–2023)
The table below shows the annual cash flow conversion efficiency of Axonics Modulation Technologies Inc from 2016 to 2023. Also see Axonics Modulation Technologies Inc total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $637.56 Million | $-2.02 Million | -0.003x | -156.50% |
| 2022-12-31 | $570.14 Million | $3.19 Million | 0.006x | +105.71% |
| 2021-12-31 | $482.44 Million | $-47.31 Million | -0.098x | +66.35% |
| 2020-12-31 | $287.37 Million | $-83.74 Million | -0.291x | +36.10% |
| 2019-12-31 | $183.00 Million | $-83.45 Million | -0.456x | -108.28% |
| 2018-12-31 | $143.28 Million | $-31.37 Million | -0.219x | -142.59% |
| 2017-12-31 | $-35.35 Million | $-18.17 Million | 0.514x | +7.59% |
| 2016-12-31 | $-36.28 Million | $-17.34 Million | 0.478x | -- |
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more